A growing collection of validated monoclonal and polyclonal antibodies, including C9orf72 poly(GP), Vacht, TDP-43, and pTDP-43.
Expanding access to ALS research tools
A critical barrier in ALS research has been access to high-quality, well-validated reagents. We are addressing this by developing and distributing reagents that are otherwise difficult to obtain.
Our goal: make reagents easily and equitably available to researchers across academia and industry, with no reach-through on intellectual property (IP) or data.
This page lists reagents currently available, with details on concentrations, validation methods, and use cases. The list is updated regularly as new reagents are developed. Antibody reagents are stored and managed by Sampled.
Purified antibody or supernatant derived from two hybridoma clones: TALS 828.179 (highly immunoreactive) and TALS 828.66. Validated in immunoassays. Available through Target ALS or the Developmental Studies Hybridoma Bank (DHSB).
References:
Wilson, K. M., et al. (2022). Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 93(7), 761–771. https://doi.org/10.1136/jnnp-2021-328710
McEachin, Z. T., et al. (2020). Chimeric peptide species contribute to divergent dipeptide repeat pathology in c9ALS/FTD and SCA36.Neuron, 107(2), 292–305.e6. https://doi.org/10.1016/j.neuron.2020.04.011
Gendron, T. F., et al. (2013). Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.Acta Neuropathologica, 126(6), 829–844. https://doi.org/10.1007/s00401-013-1192-8
Andrade, N. S., et al. (2020). Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD.Acta Neuropathologica Communications, 8(1), 111. https://doi.org/10.1186/s40478-020-00980-6
Aliquots: up to 10 per investigator (20 µL each).
Validated for ALS-relevant assays.
Proteintech #10782-2-AP.
Validated as capture antibody in ELISA immunoassays.
Available as one (1) aliquot: 150 µL at 150 µg/mL.
References:
Liu-Yesucevitz, L., Bilgutay, A., Zhang, Y.-J., Vanderweyde, T., Citro, A., et al. (2011, September 23). Correction: Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue.PLOS ONE, 6(9).https://doi.org/10.1371/annotation/7d880410-06e3-4fe3-a8f1-e84c89bcf8d0
Clone 2H610.Recognizes pathological pTDP-43 in mouse and human tissues. Available as purified aliquots for academic and industry use.
References:
Castellanos Otero, P., Todd, T. W., Shao, W., Jones, C. J., Huang, K., et al. (2024). Generation and characterization of monoclonal antibodies against pathologically phosphorylated TDP-43. PLOS ONE, 19(4), e0298080.https://doi.org/10.1371/journal.pone.0298080
(validation in-progress)
An addition to expand our suite of tools for studying protein misfolding and aggregation in ALS and related disorders.
Courtesy of Petrucelli lab, Mayo Clinic.
(validation in-progress)
An addition to expand our suite of tools for studying protein misfolding and aggregation in ALS and related disorders.
Courtesy of Petrucelli lab, Mayo Clinic.
What’s next in reagent development
Our Reagents Core is actively working to:
Expand beyond antibodies to include other hard-to-access reagents.
Standardize technical documentation, each reagent will include concentration, recommended protocols, and validation methods.
Ensure cross-linking with the Target ALS Data Engine so users can see publications and datasets where reagents have been applied.
